His book about the search for alien life, "Out There," was published on Nov

Lifespan extension in animal studies Rodent studies (most extensive data): Mice lifespan increased 20-42% with Epithalon Rats showed 12-25% lifespan extension Both maximum lifespan and median lifespan increased Healthspan (healthy years) improved even more Similar to effects seen with caloric restriction but without dietary limitation Study examples: Mechanisms of lifespan extension: Telomere preservation preventing cellular senescence Reduced oxidative damage to tissues Improved immune function preventing infections Better hormone regulation (pineal, reproductive) Reduced age-related diseases (cancer, cardiovascular) Human lifespan effects (theoretical): No completed human lifespan studies (require decades) If similar extension: 20% of 80-year lifespan = 16 additional years More realistically: Healthspan improvement more achievable than lifespan Quality of life in later years potentially enhanced Similar goals as other longevity interventions Limitations of animal data: Rodents humans (metabolism, telomere biology differ) Controlled lab conditions vs real-world human life Optimal dosing in humans unknown Long-term safety in humans not established Need rigorous human trials for validation Compare to other longevity approaches like growth hormone peptides at SeekPeptides

When your body repairs efficiently, energy improves
Standard research dose: 525mg/day oral Timing: Morning, pre-cardio or fasted Cycling: 812 weeks on / 4 weeks off is a reasonable protocol based on general NNMT inhibitor principles Form: Most sources provide capsules or powder
Its effects require intact amylin receptor signaling, as demonstrated in receptor knockout models where weight loss is abolished, and structural studies show unique conformational dynamics at these receptors compared to native amylin or other analogs
What can get lost in the fog of information is that certain peptides have solid research behind themlike GLP-1 medicationswhile others are riding on the tail of GLP-1 meds success